tirzepatide surmount 1 Clinical Trials Orals Session Lilly and Company's SURMOUNT-1 study
Description
There were no serious treatment related adverse events (TRAEs), and no TRAEs leading to study discontinuation
Additionally, the drug is still in clinical trials and has not yet been approved by the FDA for this use
You can report any suspected side effects directly to the MHRA through the Yellow Card Scheme (yellowcard.mhra.gov.uk), contributing to ongoing medication safety monitoring
KIDS AND OBESITY: NEW GUIDELINES RELEASED TO EVALUATE AND TREAT CHILDHOOD, ADOLESCENT WEIGHT ISSUES A person's lifestyle needs to be considered for a healthy approach to weight loss, he added
01200-X/asset/f2ef2727-f32c-4146-a724-f0b9312e4d9f/main.assets/gr1_lrg.jpg)
